新辅助治疗对中低位直肠癌周围肿瘤浸润淋巴细胞和树突状细胞分布的影响  

Influence of Neoadjuvant Therapy on Distribution of Tumor Infiltrating Lymphocyte and Dendritic Cell in Middle-Low Rectal Cancer

作　　者：董功航 苟剑林[2] 兰平[3,4] 

机构地区：[1]深圳市宝安区沙井人民医院普通外科,广东深圳518104 [2]重庆万州区重庆三峡中心医院普外二区,重庆万州404000 [3]中山大学附属第六医院结直肠外科 [4]中山大学胃肠研究所,广东广州510655

出　　处：《中国普外基础与临床杂志》2011年第5期537-540,共4页Chinese Journal of Bases and Clinics In General Surgery

摘　　要：目的进一步了解直肠癌新辅助治疗后肿瘤组织局部免疫状态的改变,为直肠癌新辅助治疗提供更多认识。方法选取新辅助治疗(FOLFOX6方案)的中低位直肠癌患者60例(治疗组)及未行新辅助治疗的中低位直肠癌患者60例(对照组)的术后石蜡包埋组织进行对照研究。在高倍镜下对2组癌组织标本切片进行肿瘤浸润淋巴细胞(TIL)计数,采取鼠抗人单克隆抗体S-100,采用免疫组织化学SP法检测2组癌组织中树突状细胞(DC)的形态和分布特征,并对其阳性细胞计数。结果①TIL反应情况:TIL主要集中于癌周区,聚集存在,形态不规则,核大,胞质少。治疗组的TIL反应阳性率为75.00%(45/60),对照组的TIL反应阳性率为90.00%(54/60),治疗组低于对照组(χ2=10.58,P=0.014)。②S-100阳性DC:S-100蛋白阳性标记的DC呈棕黄色,主要分布在癌组织周围,定位在细胞核和细胞浆,治疗组的S-100阳性DC数为(36.85±11.17)/HPF,对照组S-100阳性DC数为(26.50±7.68)/HPF,治疗组高于对照组(t=5.91,P=0.001)。结论新辅助治疗可使肿瘤的局部TIL减少,DC增加。Objective To learn further the local immunity changes of rectal cancer after neoadjuvant therapy and improve the cognition of this project.Methods Sixty cases of paraffin-embedded sections of the excised specimen from the two groups of middle and low rectal cancer patients,with（therapy group） or without（control group） neoadjuvant therapy,were studied respectively.Tumor infiltrating lymphocytes（TIL） in the two groups were counted under microscope,and also,dendritic cells（DC） were counted and morphology and distribution of the DCs were recorded through immunohistochemistry stain with monoclonal antibody,S-100.Results TILs and DCs in the two groups mainly assembled in the pericancerous tissues.The positive rate of TIL in therapy group was 75.00%（45/60） and 90.00%（54/60） in control group（χ2=10.58,P=0.014）.S-100 positive DCs were（36.85±11.17）/HPF versus（26.50±7.68）/HPF in the therapy group and control group,respectively（P=0.001）.Conclusion Neoadjuvant therapy for rectal cancer can influence the local tumor immunity enviroment by reducing TILs and increasing DCs.

关 键 词：直肠癌 新辅助治疗 局部免疫 

分 类 号：R735.37[医药卫生—肿瘤]